QR code

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differ...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2021-03-01
Reeks:Frontiers in Oncology
Onderwerpen:
acute myeloid leukemia
AML
enasidenib
IDH
isocitrate dehydrogenase
ivosidenib
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items